Compare INTT & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INTT | MSLE |
|---|---|---|
| Founded | 1981 | N/A |
| Country | United States | Canada |
| Employees | N/A | 17 |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.3M | 146.9M |
| IPO Year | 1997 | N/A |
| Metric | INTT | MSLE |
|---|---|---|
| Price | $14.93 | $6.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | ★ 127.2K | 120.6K |
| Earning Date | 05-01-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,801,000.00 | N/A |
| Revenue This Year | $15.82 | N/A |
| Revenue Next Year | $9.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 66.06 | N/A |
| 52 Week Low | $5.51 | $5.50 |
| 52 Week High | $15.66 | $13.39 |
| Indicator | INTT | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 59.57 | 34.94 |
| Support Level | $7.21 | N/A |
| Resistance Level | $15.34 | $7.52 |
| Average True Range (ATR) | 0.96 | 0.70 |
| MACD | -0.15 | 0.01 |
| Stochastic Oscillator | 71.72 | 24.74 |
inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.